In most subpopulations of patients with overactive bladder (OAB), the percentage of patients who respond positively to treatment is significantly higher in those who receive fesoterodine 4 or 8 mg or tolterodine extended release (ER) versus those treated with placebo, investigators announced here at the 23rd Annual Meeting of the European Association of Urology (EAU).
Importantly, the response was seen as early as two weeks and was usually maintained at the end of the 12-week treatment period.
Andrea Tubaro, MD, with Sant Andrea Hospital in Rome, Italy, and colleagues elsewhere assessed the efficacy of fesoterodine as measured by self-reported treatment response rates at two and 12 weeks in all subjects with OAB drawn from a recent phase III trial and in subpopulations stratified by sex, age, and incontinence status.
Read More
Subscribe to:
Posts (Atom)